GALDERMA
Galderma, the world’s largest independent dermatology company, announced today that Maria Teresa “Tessa” Hilado will join its Advisory Committee, effective January 1, 2022.
Ms. Hilado currently serves on the board of directors at Campbell Soup Company, Zimmer Biomet Holdings, Inc. and Pharmaceutical Product Development, LLC.
“I look forward to working with Tessa Hilado as we
move forward with Galderma’s next growth phase.
Her appointment will greatly strengthen the Advisory Committee and shows our dedication to
increasing diversity at Galderma.”
THOMAS EBELING
CHAIRMAN OF THE ADVISORY COMMITTEE, GALDERMA
A financial management specialist with over 30 years’ experience, Ms. Hilado brings a proven track record across several global corporations and brands. Her background includes pharmaceuticals, consumer products and industrials.
She most recently served as Executive Vice President and Chief Financial Officer at global pharmaceutical company Allergan PLC, from 2014 until her retirement in 2018. Prior to this, Ms. Hilado was Senior Vice President, Finance and Treasurer of PepsiCo Inc.; Vice President and Treasurer for Schering-Plough Corp.; and held several leadership roles at General Motors Company.
She holds a Bachelor of Science in Management Engineering from Ateneo de Manila University in the Philippines and an MBA from the University of Virginia Darden School of Business.
“I am thrilled to welcome Tessa to Galderma’s
Advisory Committee. Her vast expertise will be
instrumental in implementing our integrated
dermatology strategy and in fulfilling our ambition of
becoming the leading dermatology company in the
world.”
FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER, GALDERMA
About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005498/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands12.1.2026 13:30:00 CET | Press release
Cellares’ new IDMO Smart Factory in Leiden, Netherlands, expands commercial-scale manufacturing capacity for European cell therapy patient populations through a standardized, automated, and highly scalable facility model Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity. Cell therapy manufacturing is patient-specific and time-sensitive, making regional production capacity increasingly important as programs advance from clinical development toward commercial supply. The new Netherlands hub is designed to provide European drug developers with access to automated manufacturing infrastructure, while maintaining alignment to a common production stan
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas12.1.2026 13:30:00 CET | Press release
Updated national AAC protocol supports hospital-based, fully-reimbursed compassionate access across three solid tumor settings Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation d’Accès Compassionnel (AAC) framework. The updated protocol expands France’s previously granted AAC authorization for BOT+BAL in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases to eligible patients with certain ovarian cancers and soft-tissue sarcomas—diseases with substantial unmet medical need after standard options have been exhausted. The revised protocol is designed to broaden the eligibility criteria, allowing more patients with advanced solid tumors to have early access to BOT+BAL under reimbursed compassionate
Lilac and Traxys Announce Binding 10-Year Offtake Agreement for Great Salt Lake Lithium Production12.1.2026 13:00:00 CET | Press release
Definitive agreement secures 100% of Phase 1 production, advancing project toward final investment decision Lilac Solutions, a leading provider of direct lithium extraction technology, and Traxys North America, a leading global physical trader and merchant in metals and natural resources, today announced a binding 10-year offtake agreement for lithium carbonate produced at Lilac's Great Salt Lake facility in Utah. The agreement represents a major milestone in advancing the project toward construction and establishes a clear commercial pathway for one of the nearest-term domestic lithium projects in the United States. Under the terms of the definitive agreement, Traxys will purchase 50,000 tonnes of lithium carbonate over a 10-year period, representing 100% of the planned Phase 1 production capacity. The agreement is take-or-pay, with agreed pricing mechanisms linked to market indices. The Great Salt Lake Phase 1 facility is designed to produce 5,000 tonnes per annum of battery-grade li
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom